hrcak mascot   Srce   HID

Pregledni rad

INDICATIONS AND CONTRAINDICATIONS FOR PLATELET TRANSFUSIONS IN PATIENTS WITH THROMBOCYTOPENIA

Maja Tomičić
Tomislav Vuk
Željka Hundrić-Hašpl

Puni tekst: hrvatski, pdf (165 KB) str. 0-0 preuzimanja: 122* citiraj
APA 6th Edition
Tomičić, M., Vuk, T. i Hundrić-Hašpl, Ž. (2014). INDIKACIJE I KONTRAINDIKACIJE ZA PRIMJENU TROMBOCITNIH TRANSFUZIJA U BOLESNIKA S TROMBOCITOPENIJOM. Liječnički vjesnik, 136 (3-4), 0-0. Preuzeto s https://hrcak.srce.hr/172596
MLA 8th Edition
Tomičić, Maja, et al. "INDIKACIJE I KONTRAINDIKACIJE ZA PRIMJENU TROMBOCITNIH TRANSFUZIJA U BOLESNIKA S TROMBOCITOPENIJOM." Liječnički vjesnik, vol. 136, br. 3-4, 2014, str. 0-0. https://hrcak.srce.hr/172596. Citirano 20.10.2019.
Chicago 17th Edition
Tomičić, Maja, Tomislav Vuk i Željka Hundrić-Hašpl. "INDIKACIJE I KONTRAINDIKACIJE ZA PRIMJENU TROMBOCITNIH TRANSFUZIJA U BOLESNIKA S TROMBOCITOPENIJOM." Liječnički vjesnik 136, br. 3-4 (2014): 0-0. https://hrcak.srce.hr/172596
Harvard
Tomičić, M., Vuk, T., i Hundrić-Hašpl, Ž. (2014). 'INDIKACIJE I KONTRAINDIKACIJE ZA PRIMJENU TROMBOCITNIH TRANSFUZIJA U BOLESNIKA S TROMBOCITOPENIJOM', Liječnički vjesnik, 136(3-4), str. 0-0. Preuzeto s: https://hrcak.srce.hr/172596 (Datum pristupa: 20.10.2019.)
Vancouver
Tomičić M, Vuk T, Hundrić-Hašpl Ž. INDIKACIJE I KONTRAINDIKACIJE ZA PRIMJENU TROMBOCITNIH TRANSFUZIJA U BOLESNIKA S TROMBOCITOPENIJOM. Liječnički vjesnik [Internet]. 2014 [pristupljeno 20.10.2019.];136(3-4):0-0. Dostupno na: https://hrcak.srce.hr/172596
IEEE
M. Tomičić, T. Vuk i Ž. Hundrić-Hašpl, "INDIKACIJE I KONTRAINDIKACIJE ZA PRIMJENU TROMBOCITNIH TRANSFUZIJA U BOLESNIKA S TROMBOCITOPENIJOM", Liječnički vjesnik, vol.136, br. 3-4, str. 0-0, 2014. [Online]. Dostupno na: https://hrcak.srce.hr/172596. [Citirano: 20.10.2019.]

Sažetak
For more than 40 years now, platelet transfusion has provided life-saving supportive therapy to hematological patients with impaired hematopoiesis, bone marrow aplasia induced by chemotherapy, surgical patients and patients with a variety of disorders of platelet count and function. More than 2.9 million platelet components are transfused each year in Europe and 57000 in Croatia. Patients with thrombocytopenia and coagulopathy treated at intensive care units pose special challenges. It is essential to assess the potential risk of thrombogenic side effects over the benefit of stopping and preventing bleeding before platelet transfusion in these patients. Although transfusion practices including indications and contraindications for transfusion, the dose of platelets transfused and ‘transfusion trigger’ are variable and in some cases the best practices are not fully known, greater harmonization of policies might promote the quality, safety and optimal use of platelet products.

Ključne riječi
Thrombocytopenia – therapy; Platelet transfusion – contraindication; Hemorrhage – prevention and control

Hrčak ID: 172596

URI
https://hrcak.srce.hr/172596

[hrvatski]

Posjeta: 270 *